Jessica Seitzer

Jessica Seitzer is the Vice President of Genomic Operations at Intellia Therapeutics. Jessica is a researcher with over 15 years of industry experience in the development of oligonucleotide therapies as well as cell and gene therapies. Prior to joining Intellia, Jessica was at Merck working on RNAi Therapeutics with a focus on lipid nanoparticle and GalNac delivery of siRNAs. She joined Intellia in 2015 during the beginning of company’s inception. She has since built out their genomics and high throughput screening core with a focus on next generation sequencing and genomics infrastructure. Jessica has supported genomics analysis for all Intellia’s Development programs including their clinical programs for Transthyretin Amyloidosis (NTLA-2001) and Hereditary Angioedema (NTLA-2002). More recently Jessica has been focusing on continuing to expand Intellia’s genomics platform and infrastructure to support regulatory and clinical development programs for in vivo gene editing and cell therapy products.